Regulatory And Cost Barriers Are Likely To Limit Biosimilar Development And Expected Savings In The Near Future-Reference-Cited by-同舟云学术

Regulatory And Cost Barriers Are Likely To Limit Biosimilar Development And Expected Savings In The Near Future

Published:2014-06 Issue:6 Volume:33 Page:1048-1057
ISSN:0278-2715
Container-title:Health Affairs
language:en
Short-container-title:Health Affairs

Author:

Grabowski Henry G.¹,Guha Rahul²,Salgado Maria³

Affiliation:

1. Henry G. Grabowski ( ) is a professor emeritus and director of the Program in Pharmaceutical Health Economics at Duke University, in Durham, North Carolina.

2. Rahul Guha is a vice president at Cornerstone Research in New York City.

3. Maria Salgado is a principal at Cornerstone Research in San Francisco, California.

Publisher

Health Affairs (Project Hope)

Subject

Health Policy

Reference7 articles.

1. The Quantity And Quality Of Worldwide New Drug Introductions, 1982–2003

2. Characterizing Markets for Biopharmaceutical Innovations: Do Biologics Differ from Small Molecules?

3. Developing the Nation's Biosimilars Program

4. Entry and competition in generic biologics

5. Biosimilars

Cited by 44 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Why is there no biosimilar of Erbitux®?;Journal of Pharmaceutical and Biomedical Analysis;2023-09

2. Intercambialidade e aspectos farmacoeconômicos dos medicamentos biossimilares;JMPHC | Journal of Management & Primary Health Care | ISSN 2179-6750;2023-04-26

3. [Measurement-Based Procurement Approach for Biosimilars in Italy: A Position Paper];Farmeconomia. Health economics and therapeutic pathways;2023-03-29

4. Patenting and patent challenges in South Korea after introducing a patent linkage system;Globalization and Health;2022-11-12

5. Biosimilar monoclonal antibodies: Challenges and approaches towards formulation;Chemico-Biological Interactions;2022-10